NASDAQ:CLVS Clovis Oncology (CLVS) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free CLVS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.08▼$1.0952-Week Range N/AVolume1.16 million shsAverage Volume8.88 million shsMarket Capitalization$11.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Clovis Oncology alerts: Email Address Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report About Clovis Oncology Stock (NASDAQ:CLVS)Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.Read More Ad DarwinYour Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your report CLVS Stock News HeadlinesMarch 22, 2024 | msn.comClovis’ mayor is a paid member of the Valley Children’s team: what does she do?March 6, 2024 | msn.comClovis West 'Team Eagles' raises money for Leukemia & Lymphoma SocietyApril 17, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.December 10, 2023 | msn.comFresno father creates toy drive inspired by son's cancer battle: 'Toys of Hope'December 6, 2023 | msn.comOfficials: Weapon found in backpack at Clovis High SchoolNovember 30, 2023 | msn.comCity of Clovis hosts tree lighting ceremonyOctober 24, 2023 | msn.comFresno hospice nurse diagnosed with stage 4 cancerJuly 19, 2023 | thestreet.comClovis Oncology (CLVS) Stock Gains in After-Hours Trading After 'Breakthrough Therapy' DesignationApril 17, 2024 | The Bull Report (Ad)Healthcare Takes A Big Step Forward With The Help Of AIThe average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.July 6, 2023 | thestreet.comTesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial ShowsJuly 6, 2023 | thestreet.comWhy Clovis Oncology (CLVS) Stock Hit a One-Year Low TodayMay 21, 2023 | news.yahoo.comWing commander receives key to the city of ClovisMay 17, 2023 | news.yahoo.comNo air conditioning at Clovis East High as Fresno temperatures approach triple digitsMay 11, 2023 | marketwatch.comNon-Metastatic Castration Resistant Prostate Cancer (nmCRPC) Treatment Market Size with Growth Opportunities, Top Countries Data, Future TrendsMay 7, 2023 | usnews.comClovis East High SchoolMarch 22, 2023 | marketwatch.comLuteinizing Hormone Releasing Hormone (LHRH) Agonists Market Growth, Business Development and Analysis Till 2029March 22, 2023 | news.yahoo.comTo improve representation and safety, Fresno and Clovis schools need student councils | OpinionMarch 12, 2023 | bizjournals.comSilicon Valley Bank, a 'strong supporter' of Colorado tech startups, closed by regulatorsJanuary 30, 2023 | reuters.comCLVS.OJanuary 18, 2023 | seekingalpha.comCLVSQ Clovis Oncology, Inc.January 13, 2023 | forbes.comClovis OncologyJanuary 3, 2023 | wsj.comFirm Retention Summary: Clovis Oncology Inc.December 12, 2022 | reuters.comCancer drugmaker Clovis files for bankruptcy, hit by falling salesDecember 12, 2022 | benzinga.comThinking about buying stock in Clovis Oncology, Bank of America, Rivian Automotive, Rent the Runway, or Vipshop Holdings?December 12, 2022 | bizjournals.comBoulder drugmaker Clovis Oncology files for bankruptcyDecember 12, 2022 | finance.yahoo.comClovis Plans to Sell Cancer Drug to Novartis in Bankruptcy DealDecember 12, 2022 | finance.yahoo.comClovis (CLVS) Files for Bankruptcy Amid Lack of Financial AidSee More Headlines Receive CLVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clovis Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/03/2021Today4/17/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:CLVS CUSIP18946410 CIK1466301 Webwww.clovisoncology.com Phone303-625-5000Fax303-245-0360EmployeesN/AYear Founded2009Profitability EPS (Most Recent Fiscal Year)($1.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-264,520,000.00 Net Margins-189.37% Pretax Margin-189.68% Return on EquityN/A Return on Assets-57.78% Debt Debt-to-Equity RatioN/A Current Ratio0.14 Quick Ratio0.12 Sales & Book Value Annual Sales$148.76 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($2.15) per share Price / BookN/AMiscellaneous Outstanding Shares144,955,000Free Float138,577,000Market Cap$11.60 million OptionableOptionable Beta0.24 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesMr. Patrick J. Mahaffy MA (Age 55)Co-Founder, Chief Exec. Officer, Pres and Exec. Director Dr. Gillian C. Ivers-Read BSc (Age 64)Co-Founder, Chief Regulatory Officer and Exec. VP of Technical Operations Mr. Daniel W. Muehl CPA (Age 54)Sr. VP of Fin. and Principal Financial & Accounting Officer Dr. Lindsey Rolfe BSc (Age 50)MB ChB, MRCP, FFPM, Chief Medical Officer and Exec. VP of Clinical, Preclinical Devel. & Pharmacovigilance Mr. Corwin Dale Hooks (Age 51)Chief Commercial Officer and Sr. VP Key CompetitorsMolecular TemplatesNASDAQ:MTEMFortress BiotechNASDAQ:FBIOBolt BiotherapeuticsNASDAQ:BOLTEterna TherapeuticsNASDAQ:ERNAMIRA PharmaceuticalsNASDAQ:MIRAView All Competitors CLVS Stock Analysis - Frequently Asked Questions How were Clovis Oncology's earnings last quarter? Clovis Oncology (NASDAQ:CLVS) announced its quarterly earnings data on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by $0.08. The biopharmaceutical company had revenue of $37.92 million for the quarter, compared to analyst estimates of $38.73 million. During the same quarter last year, the firm posted ($0.89) EPS. What is Patrick J. Mahaffy's approval rating as Clovis Oncology's CEO? 12 employees have rated Clovis Oncology Chief Executive Officer Patrick J. Mahaffy on Glassdoor.com. Patrick J. Mahaffy has an approval rating of 49% among the company's employees. This puts Patrick J. Mahaffy in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Clovis Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clovis Oncology investors own include Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Tesla (TSLA), Amarin (AMRN), Intercept Pharmaceuticals (ICPT), Netflix (NFLX) and Alibaba Group (BABA). This page (NASDAQ:CLVS) was last updated on 4/17/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe “Perfect Storm” for GoldGold Safe ExchangeThe "Smart Money" Is Ready for May 1st Are You?Stansberry ResearchOptions trading has suddenly become more reliable.Eagle PublishingTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market AlertsYou won't believe what Citigroup just did to it's depositorsAmerican Alternative Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clovis Oncology Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.